Wockhardt Ltd is a leading pharmaceutical and healthcare company. Based in Mumbai, it manufactures and markets active pharmaceutical ingredients (APIs), biopharmaceutical formulations, vaccines and branded drugs. Wockhardt also runs a chain of six super specialty tertiary care healthcare facilities.
Wockhardt was founded by Dr. Habil Khorakiwala in 1967. The company commissioned its first manufacturing plant in Aurangabad, Maharashtra.
Since then, the pharma company has evolved into a research-based, global biotech enterprise which draws more than two-thirds of its revenue from overseas markets.
Wockhardt has 15 modern manufacturing plants across India, US, UK, Ireland and UAE which produce APIs, biopharmaceutical formulations and pharmaceuticals. The company produces all types of dosage forms such as sterile injectables and lyophilised products at its manufacturing facilities.
Wockhardt claims to be the only firm in the world which received QIDP status (Qualified Infectious Disease Product) from the United States Food and Drug Administration (USFDA) for six antibacterial discovery programmes.
Wockhardt employs around 2,600 people and 27 nationalities having a presence in US, UK, Ireland, Switzerland, France, Mexico and Russia.
Business operations
New drug discovery:
Wockhardt is focusing on antibiotic drug discovery and has a portfolio of innovative products and new drug delivery systems. It has a pipeline of new drugs under development.
Wockhardt launched Emrok and Emrok O in India. Around 47,000 patients were treated with the product.
Biologicals in diabetes:
Wockhardt’s biologicals segment focuses on the development of anti-diabetic l products at its R&D facility in Aurangabad. The business vertical was set up in 2004. The company holds 45 patents in biosimilar and biobetter development phases.
The product range under the vertical includes rapid-acting, fast-acting and long-acting insulin formulations. It also offers a locally-developed insulin pen.
Branded pharmaceuticals:
Wockhardt’s core business is the development, production and sales of branded drugs across therapeutic segments. Biopharmaceuticals, branded generics, finished formulations, over-the-counter and prescription products are part of its branded pharmaceutical vertical.
Vaccines:
The company has been into vaccine manufacturing for more than 20 years. It has a modern vaccine manufacturing plant in the UK. Wockhardt was a major contributor to the global fight against COVID-19 as its UK plant produced a COVID-19 vaccine that was developed by Oxford University and AstraZeneca.
The plant, located in Wrexham, North Wales, can produce millions of doses of vaccines each week. Wockhardt also has a vaccine manufacturing plant in Shendra near Aurangabad.
Contract manufacturing:
With a strong portfolio of 15 manufacturing plants, 11 in India and one each in the US, UK, Ireland & UAE, Wockhardt offers outsourcing services to pharmaceutical companies as a third-party manufacturer.
API:
The company is a leading manufacturer of API products. Its R&D capabilities, global manufacturing facilities, compliance with regulatory requirements in developed markets, strengthen its position as a key APi supplier.
Wockhardt’s market capitalisation was over ₹7,000 crore on January 3, 2024. Wockhardt share price has gone up 1.99% in the last three years.
Financials highlights
Total revenue in FY23 at ₹2,693 crore against ₹3,239 crore in FY22.
The EBITDA stood at ₹143 crore in FY23 against ₹307 crore in FY22.
Wockhardt’s EBITDA margin was 5.3% in FY23 against 9.5% in the previous year.
Net loss at ₹621 crore in FY23 against ₹279 crore in FY22.
Wockhardt Financial Highlights
- Revenue: Wockhardt reported revenue of ₹3,484.00 crore in FY26 vs ₹3,074.00 crore in FY25. It showed an increase of 13.34% on a yearly basis.
- Operating Profit: Wockhardt reported an operating profit of ₹238.00 crore in FY26 vs ₹16.00 crore in FY25. It showed an increase of 1,587.50% on a year-on-year basis.
- Net Profit: Wockhardt reported a net profit of ₹199.00 crore in FY26 vs ₹57.00 crore in FY25. It showed an increase of 449.12% on a yearly basis.
Wockhardt Quarterly Result Highlights
- Wockhardt reported revenue of ₹1,010.00 crore in Mar 2026, compared with ₹913.00 crore in Dec 2025, representing an increase of 10.62% on a quarter-on-quarter (QoQ) basis.
- Wockhardt reported an operating profit of ₹189.00 crore in Mar 2026, compared with ₹67.00 crore in Dec 2025, representing an increase of 182.09% on a quarter-on-quarter (QoQ) basis.
- Wockhardt reported a profit of ₹164.00 crore in Mar 2026, compared with ₹61.00 crore in Dec 2025, reflecting an increase of 168.85% on a QoQ basis.
- The earnings per share (EPS) of Wockhardt stood at ₹3.02 during Mar 2026.
